Inactive Instrument

VectivBio Holding AG

VECT

CH1109007893

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VECT, RTL, APGN

June 01, 2023 at 02:42 pm

NEW YORK, June 1, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Halper Sadeh LLC (PRNewsfoto/Halper Sadeh LLP)

VectivBio Holding AG (NASDAQ: VECT)'s sale to Ironwood Pharmaceuticals, Inc. for $17.00 per share. If you are a VectivBio shareholder, click here to learn more about your rights and options.

The Necessity Retail REIT Inc. (NASDAQ: RTL)'s sale to Global Net Lease Inc. for 0.670 shares of Global Net for each common share of Necessity Retail. Upon closing of the proposed transaction, Necessity Retail stockholders are expected to own approximately 39% of the combined company. If you are a Necessity Retail shareholder, click here to learn more about your rights and options.

Apexigen, Inc. (NASDAQ: APGN)'s sale to Pyxis Oncology, Inc. for 0.1725 shares of Pyxis for each share of Apexigen. If you are an Apexigen shareholder, click here to learn more about your rights and options.

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-vect-rtl-apgn-301839976.html

SOURCE Halper Sadeh LLP

Latest news about VectivBio Holding AG

VectivBio Holding AG(NasdaqGS:VECT) dropped from NASDAQ Composite Index	07/07/23	CI
Sector Update: Health Care Stocks Advancing Late Thursday	29/06/23	MT
Sector Update: Health Care Stocks Higher Thursday Afternoon	29/06/23	MT
Ironwood Pharmaceuticals, VectivBio Say Tender Offer for VectivBio Shares Completed	29/06/23	MT
Ironwood Pharmaceuticals, Inc. completed the acquisition of VectivBio Holding AG from Versant Venture Capital V, L.P., managed by Versant Venture Management, LLC, Forbion Growth Opportunities Fund II, managed by Forbion Capital Partners B.V., OrbiMed Advisors LLC and others.	28/06/23	CI
VectivBio Says Takeover by Ironwood Pharmaceuticals Approved at Extraordinary Shareholder Meeting	26/06/23	MT
Ironwood Pharmaceuticals Tender Offer for VectivBio Clears Antitrust Waiting Period	16/06/23	MT
VectivBio Holding Ag Approves Amendments to the Articles of Association	02/06/23	CI
Credit Suisse Downgrades VectivBio Holding to Neutral From Outperform on Heels of Announced Sale to Ironwood Pharmaceuticals, Lowers PT to $17 From $22	23/05/23	MT
Piper Sandler Downgrades VectivBio to Neutral From Overweight, Adjusts Price Target to $17 From $25	23/05/23	MT
SVB Securities Downgrades VectivBio to Market Perform From Outperform, Adjusts Price Target to $17 From $30	23/05/23	MT
Health Care Up Slightly as Pfizer Rallies on Weight-Drug Hopes -- Health Care Roundup	22/05/23	DJ
Ironwood Pharmaceuticals to Buy VectivBio for $1 Billion, Enhancing Gastrointestinal Portfolio	22/05/23	MT
Ironwood bulks up on digestive therapies with $1.15 billion VectivBio buy	22/05/23	RE
Ironwood Pharmaceuticals to Acquire Switzerland-Based VectivBio for About $1 Billion	22/05/23	MT
Transcript : Ironwood Pharmaceuticals, Inc., VectivBio Holding AG - M&A Call	22/05/23
Ironwood Pharma To Acquire VectivBio For $1.15 Billion	22/05/23	RE
Ironwood bulks up on digestive therapies with $1.15 bln VectivBio buy	22/05/23	RE
Ironwood Pharma to acquire Swiss-based VectivBio in $1 bln deal	22/05/23	RE
Ironwood Pharmaceuticals, Inc. entered into definitive agreement to acquire VectivBio Holding AG for $1 billion.	21/05/23	CI
Piper Sandler Adjusts VectivBio Price Target to $25 From $23, Maintains Overweight Rating	20/04/23	MT
Transcript : VectivBio Holding AG, 2022 Earnings Call, Apr 19, 2023	19/04/23
VectivBio Reports Narrower Loss for Full-Year 2022	19/04/23	MT
VectivBio Holding AG Reports Earnings Results for the Full Year Ended December 31, 2022	19/04/23	CI
VectivBio Holding, Asahi Kasei Pharma Initiate Phase 1 Trial in Japan for Short Bowel Syndrome Treatment	13/03/23	MT

Chart VectivBio Holding AG

Duration

Period

More charts

Company Profile

VectivBio Holding AG is a holding company based in Switzerland. The Company trough it's subsidiaries operates as a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe rare conditions for which there is a significant unmet medical need.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+31.06%	682B
NOVO NORDISK A/S	+30.35%	586B
JOHNSON & JOHNSON	-3.42%	364B
MERCK & CO., INC.	+18.02%	327B
ABBVIE INC.	+4.27%	285B
ASTRAZENECA PLC	+15.53%	240B
NOVARTIS AG	+10.16%	209B
ROCHE HOLDING AG	-8.14%	203B
AMGEN INC.	+8.12%	165B

Other Pharmaceuticals